Drug Search Results
More Filters [+]

CMN-009

Alternative Names: CMN-009, CMN009, CMN 009
Latest Update: 2023-06-27
Latest Update Note: News Article

Product Description

CMN009 is an IL-18 armored anti-DLL3 CAR-CIK therapeutic for SCLC. (Sourced from: https://www.benzinga.com/pressreleases/23/06/n33020925/coimmune-obtains-license-to-target-dll3-with-il-18-armored-car-technology)

Mechanisms of Action: DLL3 Modulator

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CoImmune
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CMN-009

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events